Lupus erythematosus, systemic Trials in New York, United States
Conditions / Lupus erythematosus, systemic / New York, United States
Clinical trials for Lupus erythematosus, systemic investigate a range of treatment strategies and patient populations.
22 total trials for this combination
Showing top 10 of 22 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03517722 | A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus | TERMINATED | PHASE3 |
| NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | RECRUITING | — |
| NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | RECRUITING | — |
| NCT00137969 | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus | COMPLETED | PHASE2/PHASE3 |
| NCT00089804 | Study of LJP 394 in Lupus Patients With History of Renal Disease | TERMINATED | PHASE3 |
| NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | RECRUITING | — |
| NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | RECRUITING | — |
| NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | RECRUITING | — |
| NCT03161483 | A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus | COMPLETED | PHASE2 |
| NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | RECRUITING | — |